Literature DB >> 32053714

Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine.

Andrew M Blumenfeld1, Lars Edvinsson2, Abhijeet Jakate3, Pradeep Banerjee3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32053714

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


× No keyword cloud information.
  3 in total

1.  Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.

Authors:  Abhijeet Jakate; Andrew M Blumenfeld; Ramesh Boinpally; Matthew Butler; Lisa Borbridge; Janette Contreras-De Lama; Danielle McGeeney; Antonia Periclou; Richard B Lipton
Journal:  Headache       Date:  2021-04-05       Impact factor: 5.887

2.  Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.

Authors:  Ramesh Boinpally; Kaifeng Lu
Journal:  Clin Pharmacol Drug Dev       Date:  2022-02-16

3.  Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.

Authors:  Andrew M Blumenfeld; Kerry Knievel; Aubrey Manack Adams; Lawrence Severt; Matthew Butler; Hongxin Lai; David W Dodick
Journal:  Adv Ther       Date:  2021-12-07       Impact factor: 4.070
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.